<DOC>
	<DOCNO>NCT00448643</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Radiation therapy may also make tumor cell sensitive cisplatin . Giving radiation therapy together cisplatin surgery may kill tumor cell remain surgery . PURPOSE : This phase I trial study side effect best dose whole-abdominal radiation therapy give together cisplatin treat patient stage III stage IV endometrial cancer remove surgery .</brief_summary>
	<brief_title>Whole-Abdominal Radiation Therapy Cisplatin Treating Patients With Stage III Stage IV Endometrial Cancer That Has Been Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine recommend phase II dose adjuvant whole-abdominal radiotherapy administer cisplatin patient optimally debulked stage III IV carcinoma endometrium . OUTLINE : This dose-escalation study whole-abdominal radiotherapy ( WAR ) . Patients receive 3 course standard chemotherapy comprise carboplatin IV paclitaxel IV . Beginning within 6 week completion standard chemotherapy , patient receive cisplatin IV 30-60 minute undergo single fraction WAR day 1 . Treatment cisplatin WAR repeat weekly 6 course absence disease progression unacceptable toxicity . Patients may undergo standard vaginal brachytherapy begin early last course standard chemotherapy later 1 week start cisplatin WAR . Cohorts 3-6 patient receive escalate dos WAR recommend phase II dose ( RPTD ) determine . The RPTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated RPTD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis endometrial cancer , include follow cellular type : Papillary serous carcinoma Clear cell carcinoma Adenocarcinoma Stage III IV disease No evidence extraabdominal extension disease ( e.g. , groin node , lung , supraclavicular node ) Has undergone totalabdominal hysterectomy , surgical removal present fallopian tube ovary , resection palpable lymph node pelvis paraaortic region ( surgical sampling nodal region palpable node present ) within past 6 week Peritoneal washing must collect cytological evaluation Must ≤ 1 cm residual disease surgery PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy ≥ 6 month WBC ≥ 3,000/mm^3 Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine &lt; 2.0 mg/dL Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Lactate dehydrogenase &lt; 3 time ULN Gamma glutamyl transferase &lt; 3 time ULN SGPT SGOT &lt; 3 time ULN Alkaline phosphatase &lt; 3 time ULN No malignant tumor within past 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy whole abdomen and/or pelvis/vagina No systemic chemotherapy within past 5 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>endometrial clear cell carcinoma</keyword>
	<keyword>endometrial papillary carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
</DOC>